-

Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of LUMIFY Preservative Free redness reliever eye drops, the first and only preservative-free over-the-counter eye drops with low-dose brimonidine tartrate 0.025% that relieve redness of the eye due to minor eye irritations.

“Consumers often say how amazed they are at the difference our original LUMIFY makes to their eyes, with over 50,000 five-star reviews as proof,” said John Ferris, president, Consumer, Bausch + Lomb. “LUMIFY Preservative Free brings that same fast-acting formula to those with sensitive eyes — delivering a visibly brighter, whiter look in just 60 seconds.”

Before LUMIFY eye drops were introduced in 2018, redness relievers relied on the same ingredients for decades, which had well known side effects. LUMIFY and LUMIFY Preservative Free are the only over-the-counter redness relievers that selectively target eye redness and offer excellent results with a lower risk of rebound redness and loss of efficacy when used as directed.

“LUMIFY delivers consistently proven results for patients experiencing eye redness,” said Melissa Toyos, MD, and partner, Toyos Clinic, Nashville, TN. “With LUMIFY Preservative Free, my patients with eye sensitivities now have an option that’s just as effective as the original LUMIFY redness reliever eye drops.”

LUMIFY Preservative Free is now available in convenient single-use vials at most U.S. retailers nationwide, including Walmart, Target, CVS, Walgreens, Rite Aid and Amazon. The eye drops will have a manufacturer's suggested retail price of $26.99 and feature updated premium packaging consistent with LUMIFY.

For more information on the LUMIFY brand visit www.lumifyeyes.com.

About the LUMIFY Brand
The LUMIFY brand began in 2018 with the U.S. launch of LUMIFY redness reliever eye drops. They are the No. 1 eye doctor recommended redness reliever eye drop brand with approximately 90% of doctor recommendations1 and have grown double digits every year since launching. In 2023, Bausch + Lomb introduced LUMIFY EYE ILLUMINATIONS™, a line of specialty eye care products specifically developed for the sensitive area around the eyes. The FDA approved LUMIFY Preservative Free eye drops in April 2024. For more information on the LUMIFY brand, visit www.lumifyeyes.com.

About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

References

  1. IQVIA, Average Share of Weekly Doctor Recommendations, January to March 2025.

©2025 Bausch + Lomb.
LUM.0130.USA.25

Contacts

Media Contact:
Kristy Marks
kristy.marks@bausch.com
(908) 927-0683

Bausch + Lomb Corporation

NYSE:BLCO

Release Versions

Contacts

Media Contact:
Kristy Marks
kristy.marks@bausch.com
(908) 927-0683

More News From Bausch + Lomb Corporation

Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that it will deliver more than 40 scientific data presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting taking place in Denver, CO, May 3-7, 2026. Scientific posters and papers will highlight the results of various studies across the company’s broad portfolio of products...

Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2026 financial results. “We’re doing exactly what we said we would: driving sustainable growth and margin expansion, improving how we sell and operate and continuing to invest in a pipeline that will carry us forward,” said Brent Saunders, chairman and CEO, Bausch + Lomb. Select Company Highlig...

Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Ophthalmology and Therapy published a narrative review highlighting the role of certain B vitamins in reducing the risk of development and progression of AMD1, a leading cause of vision loss in Americans 50 years of age or older.2 Drawing on more than two decades of scientific research, the publication synt...
Back to Newsroom